Skip to main content
logo
KalVista Pharmaceuticals, Inc. (KALV)
Jun 11, 2026 - KALV was delisted (reason: acquired by Chiesi Group)
27.00
+0.01 (0.04%)
Inactive · Last trade price on Jun 10, 2026

KalVista Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Dec '25 Apr '25 Apr '24 Apr '23 Apr '22
Revenue
-49.08----
Revenue Growth
------
Gross Profit
-46----
Operating Income
-177.49-112.04-188-140.45-110.87-96.61
Net Income
-183.43-109.52-183.44-126.64-92.91-82.34
Earnings Per Share
-3.42-2.15-3.69-3.44-3.33-3.36
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Dec '25 Apr '25 Apr '24 Apr '23 Apr '22
Cash & Investments
285.03300.21220.62210.4149.38166.2
Total Debt
151.5151.586.317.328.238.19
Net Cash (Debt)
133.53148.64214.31203.08141.14158.01
Net Cash Growth
-37.69%-30.64%5.53%43.89%-10.68%-34.98%
Net Cash Per Share
2.492.924.325.525.066.46

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Apr '25 Apr '24 Apr '23 Apr '22 Apr '21
Operating Cash Flow
-152.6-152.91-89.23-75.26-78.13-30.17
Capital Expenditures
-2.3-0.43-0.04-1.2-0.93-0.08
Free Cash Flow
-154.9-153.34-89.27-76.46-79.07-30.25
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Dec '25 Apr '25 Apr '24 Apr '23 Apr '22
Gross Margin
-93.72%----
Operating Margin
--228.28%----
Pretax Margin
--225.27%----
Profit Margin
--223.16%----
FCF Margin
-0.00%----

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2025FY 2024FY 2023FY 2022
Period EndingJul '26 Dec '25 Apr '25 Apr '24 Apr '23 Apr '22
PS Ratio
12.5616.75----